Redcare Pharmacy stock gains as Deutsche Bank reiterates Buy rating

Redcare Pharmacy stock (ISIN NL0012044747) is trading higher after Deutsche Bank Research reiterated its Buy rating on September 18, 2026, seeing the recent pullback as an attractive entry point for investors. As of September 21, 2026, the shares changed hands at 62.90 euros on Xetra, compared with around 60.30 euros at the time of the latest rating update, implying a gain of about 4.3 percent over this period.

Deutsche Bank stays positive on recent weakness

According to finanzen.ch on September 18, 2026, Deutsche Bank Research reaffirmed its Buy recommendation for Redcare Pharmacy, describing the latest share-price weakness as a particularly attractive buying opportunity.

In that analysis, Deutsche Bank highlighted Redcare Pharmacy as a Buy idea in a so-called catalyst call, emphasizing that the fundamental investment case remains intact despite short-term volatility. The note referenced a share price of around 60.30 euros at the time of the report, while the stock had already recovered to approximately 62.10 euros, indicating a roughly 3.0 percent rebound over a short time frame, which underpins the bank's view that investors are willing to step back in on dips.

Option markets point to elevated volatility

As Saxo reported on September 19, 2026, Redcare Pharmacy appeared among a group of stocks where option premiums stood out at the September monthly expiry.

According to Saxo's option-market overview, Redcare Pharmacy, traded under the ticker RDC in that context, showed implied volatility of 55.4 with a rank of 95 and a percentile of 44, placing it near the top of its recent volatility range while only slightly above its median day. This combination suggests that, at least for now, the market is assigning a relatively high volatility premium but not one that is extreme by the stock's own recent standards, a nuance that can matter for investors considering option strategies around the shares.

Stock price, trading venue and volatility context

Redcare Pharmacy is primarily listed on Xetra, where the stock traded at 62.90 euros as of September 21, 2026, with an intraday gain of 3.95 percent compared with the previous close, based on exchange data for that day. This price represents a notable recovery from levels around 60.30 euros cited in mid-September 2026 analyst commentary and sits modestly above the 62.10-euro level mentioned in the same analysis, reflecting how the share price has continued to edge higher over a few sessions.

The same pricing snapshot places Redcare Pharmacy's latest move within a broader volatility framework described by Saxo, where implied volatility at 55.4 places the stock near the upper end of its recent range but not at an extreme, implying that while markets expect sizable price swings, they are not yet pricing in extraordinary stress. For investors, this means that recent gains and an elevated volatility backdrop coexist, and the balance between them may influence how they evaluate Deutsche Bank's reiterated Buy stance and any future moves in the stock.

Redcare Pharmacy stock at a glance

As of September 21, 2026, Redcare Pharmacy stock closed at 62.90 euros on Xetra, representing the primary reference price for the shares in their home market.

More news and analyses on Redcare Pharmacy stock